The age-related disease drug developer, which counts Mayo Clinic and WuXi PharmaTech as investors, raised $55m as recently as last month.
US-based anti-aging therapy developer Unity Biotechnology filed on Friday for an $85m initial public offering that will allow pharmaceutical research firms WuXi PharmaTech and Mayo Clinic to exit.
Unity is developing treatments for age-related conditions such as arthritis, vision loss or cognitive decline. The IPO proceeds will fund a phase 1 clinical trial for its lead product candidate, a senolytic molecule treatment for osteoarthritis called UBX0101.
Additional capital will go to a phase 1 clinical study for a second…
